Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort
Abstract
OBJECTIVE: Predicting relapse is a major challenge in schizophrenia from a clinical and medico-economic point of view. During recent decades, major psychiatric disorders have been found to be extensively associated with metabolic disorders, even before the illness onset, with a prevalence estimated to be 35% in this population. However, no study to date has, to our knowledge, explored the potential impact of metabolic syndrome (MetS) on relapse. METHODS: From 2010 to 2016, 185 patients (mean age = 32 years) with a DSM-IV-TR diagnosis of schizophrenia were included in the FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) cohort and followed up for 1 year. Multivariable logistic regression was performed to estimate the adjusted odds ratio for relapse. RESULTS: Thirty-seven percent of stabilized outpatients with schizophrenia (mean illness duration = 11 years) experienced a relapse at least once during the 1 year of follow-up. MetS strongly predicted relapse at 1 year, independently of illness severity, insight into illness, and treatment characteristics (including medication compliance). Patients with MetS at baseline had a 3 times higher risk (95% CI, 1.1-8.4) of experiencing a new episode of psychosis during the 12 months of follow-up. CONCLUSIONS: Further studies should determine if reducing or preventing MetS could help to protect subjects with schizophrenia from relapse.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clozapine is the only approved antipsychotic medication for people with treatment-resistant schizophrenia.
“Clozapine is the only approved antipsychotic medication for people with treatment-resistant schizophrenia 164 .”
From The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness (2019) · cites this paper as [164]
Cites
Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
Correll, C. U., Brevig, T., & Brain, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s234813 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531 · see citing works
Costa-Dookhan, K. A., Agarwal, S. M., Chintoh, A. F., Tran, V., Stogios, N., Ebdrup, B. H., Sockalingam, S., Rajji, T. K., Remington, G. J., Siskind, D. J., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1698545 · Cited by 58 · see citing works
Maurus, I., Wagner, S. A., Spaeth, J., Vogel, A., Muenz, S., Seitz, V., von Philipsborn, P., Solmi, M., Firth, J., Stubbs, B., et al. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1766 · Cited by 51 · see citing works
Joseph, A., Moriceau, S., Sica, V., Anagnostopoulos, G., Pol, J., Martins, I., Lafarge, A., Maiuri, M. C., Leboyer, M., Loftus, J., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2716-5 · Cited by 44 · see citing works
Self-citationGäebel, W., Stricker, J. H., & Riesbeck, M. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.10.049 · Cited by 35 · see citing works
Fang, X., Chen, L., Wang, D., Yu, L., Wang, Y., Chen, Y., Ren, J., Tang, W., & Zhang, C. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112522 · Cited by 29 · see citing works
Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication
Morell, R., Curtis, J., Watkins, A., Poole, J., Fibbins, H., Rossimel, E., Gerrard, M., White, A., Teasdale, S. B., Ward, P. B., et al. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112606 · Cited by 25 · see citing works
Salloum, N. C., D, M. F. M., Ball, S., & Papakostas, G. I. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0646-3 · Cited by 20 · see citing works
Multimorbidity and the Etiology of Schizophrenia
Szöke, A., Pignon, B., Godin, O., Ferchiou, A., Tamouza, R., Leboyer, M., & Schürhoff, F. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01500-9 · Cited by 19 · see citing works
Self-citationExploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists
Correll, C. U., Brevig, T., & Brain, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s234813 · Cited by 17 · see citing works
Shymko, G., Grace, T., Jolly, N., Dobson, L., Hacking, D., Parmar, A., Kapi, P., & Waters, F. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13013 · Cited by 17 · see citing works
Higher Body-Mass Index and Lower Gray Matter Volumes in First Episode of Psychosis
Kolenič, M., Španiel, F., Hlinka, J., Matějka, M., Knytl, P., Šebela, A., Renka, J., & Hájek, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.556759 · Cited by 17 · see citing works
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Meyer, J. M., & Correll, C. U. (2023) · CNS Drugs · doi:10.1007/s40263-023-01022-7 · Cited by 16 · see citing works
Foiselle, M., Barbosa, S., Godin, O., Wu, C., Boukouaci, W., André, M., Aouizerate, B., Berna, F. S., Barau, C., Capdevielle, D., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100436 · Cited by 14 · see citing works
Self-citationPawełczyk, T., Grancow-Grabka, M., Żurner, N., & Pawełczyk, A. M. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.02.012 · Cited by 14 · see citing works
Fond, G. B., Godin, O., Dumontaud, M., Faget, C., Schürhoff, F., Berna, F. S., Aouizerate, B., Capdevielle, D., Chéreau, I., d’Amato, T., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109654 · Cited by 14 · see citing works
Self-citationKahve, A. C., Kaya, H., Azarsız, Y. D., Çakıl, A. G., & Göka, E. (2021) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12824 · Cited by 13 · see citing works
Liao, X., Ye, H., & Si, T. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s294521 · Cited by 13 · see citing works
Fond, G. B., Faugère, M., Richieri, R. M., Cermolacce, M., Korchia, T., Micoulaud‐Franchi, J., de Verville, P. L. S., Boyer, L., & Lançon, C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.046 · Cited by 11 · see citing works
Self-citationGodin, O., Pignon, B., Szöke, A., Boyer, L., Aouizerate, B., Schorr, B., André, M., Capdevielle, D., Chéreau, I., Coulon, N., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110641 · Cited by 10 · see citing works
Self-citationGündoğmuş, İ., Aydın, M. B., Öz, S., Taşçi, A. B., & Uzun, Ö. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000377 · Cited by 9 · see citing works
Tay, J. L., Ang, Y. L., Tam, W., & Sim, K. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-084463 · Cited by 8 · see citing works
Godin, O., Olié, É., Fond, G. B., Aouizerate, B., Aubin, V., Bellivier, F., Belzeaux-R, R., Courtet, P., Dubertret, C., Haffen, É., et al. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13655 · Cited by 8 · see citing works
Self-citationTay, J. L., Htun, K. K., & Sim, K. (2024) · Brain Sciences · doi:10.3390/brainsci14090878 · Cited by 7 · see citing works
Morris, A., Reed, T., McBride, G., & Chen, J. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.056 · Cited by 7 · see citing works
Jiang, D., Wang, R., Ma, D., Tang, C. L., Liu, Y., Jian, N., Luo, J., Gong, Q., & Chen, Y. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.05.027 · Cited by 7 · see citing works
Saitoh, K., Lajnef, M., Boukouaci, W., André, M., Andrieu, C., Aouizerate, B., Barau, C., Bouassida, J., Capdevielle, D., Chéreau, I., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116557 · Cited by 4 · see citing works
Self-citationCorrelates of Metabolic Syndrome in Patients with Schizophrenia: An Exploratory Study
Nebhinani, N., Tripathi, S., Suthar, N., Pareek, V., Purohit, P., & Sharma, P. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00912-7 · Cited by 5 · see citing works
Barbosa, S., Tamouza, R., Leboyer, M., Aouizerate, B., Andrieu, C., André, M., Boukouaci, W., Capdevielle, D., Chéreau, I., Clauss, J. M. E., et al. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111304 · Cited by 3 · see citing works
Self-citationTang, W., Guan, C., Zhangbin, L., Xinmiao, Z., & Cui, H. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117106 · Cited by 1 · see citing works
Taniguchi, R., Esaki, Y., Obayashi, K., Saeki, K., Tsuboi, S., Fujita, K., Iwata, N., & Kitajima, T. (2026) · SLEEP · doi:10.1093/sleep/zsag177 · Cited by 1 · see citing works
Impact de la personnalité sur les symptômes neuropsychiatriques de la maladie d'Alzheimer débutante
Dorey, J. (2020) · doi:10.70675/6915b759zcd52z439az81eczae459aaa145b
Self-citationMetabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)
Joseph, A. (2021) · theses.fr (ABES) · doi:10.70675/b045685ezd444z4b46zb0f9z0e726ceac466
Wu, H., Han, Y., Wen, Z., Liu, W., Tu, N., Yang, W., Li, J., & Zha, Y. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag039
- Authors
- Godin, O., Leboyer, M., Schürhoff, F., Llorca, P.-M., Boyer, L., Andre, M., Andrianarisoa, M., Aouizerate, B., Berna, F., Capdevielle, D., Chereau, I., Dorey, J.-M., Dubertret, C., Dubreucq, J., Faget, C., Lancon, C., Leignier, S., Mallet, J., Misdrahi, D., Passerieux, C., Rey, R., Roux, P., Vidailhet, P., Costagliola, D., Fond, G., & for the FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group
- Affiliations
- Inserm (FR)
- Université Clermont Auvergne (FR)
- Laboratoire Hubert Curien (FR)
- Université de Bordeaux (FR)
- Lyon 1 Université (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Centre National de la Recherche Scientifique (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2018-09-18
- Volume
- 79
- Issue
- 6
- Pages
- 17m12007
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W2892124744
- Cited by
- 34
- References
- 1
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 7 · 2019: 7
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-11-IDEX-0004)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, metabolic syndrome, recurrence prediction, disease severity, metabolic disorders, medication adherence, insight into illness
- MeSH terms
- Adult, France, Humans, Longitudinal Studies, Recurrence, Risk Factors, Schizophrenia, Severity of Illness Index, Antipsychotic Agents, Logistic Models, Case-Control Studies, Metabolic Syndrome, Medication Adherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
